Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

Cited In for PubMed (Select 12958164)


Potential of adipose-derived stem cells in muscular regenerative therapies.

Forcales SV.

Front Aging Neurosci. 2015 Jul 13;7:123. doi: 10.3389/fnagi.2015.00123. eCollection 2015. Review.


Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy.

Iyer CC, McGovern VL, Wise DO, Glass DJ, Burghes AH.

Neuromuscul Disord. 2014 May;24(5):436-44. doi: 10.1016/j.nmd.2014.02.007. Epub 2014 Feb 25.


Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.

Hindi SM, Sato S, Choi Y, Kumar A.

Hum Mol Genet. 2014 Mar 15;23(6):1492-505. doi: 10.1093/hmg/ddt536. Epub 2013 Oct 24.


Efficacy of muscle exercise in patients with muscular dystrophy: a systematic review showing a missed opportunity to improve outcomes.

Gianola S, Pecoraro V, Lambiase S, Gatti R, Banfi G, Moja L.

PLoS One. 2013 Jun 12;8(6):e65414. doi: 10.1371/journal.pone.0065414. Print 2013. Review.


A novel in vitro model for studying quiescence and activation of primary isolated human myoblasts.

Sellathurai J, Cheedipudi S, Dhawan J, Schrøder HD.

PLoS One. 2013 May 23;8(5):e64067. doi: 10.1371/journal.pone.0064067. Print 2013.


Wasting mechanisms in muscular dystrophy.

Shin J, Tajrishi MM, Ogura Y, Kumar A.

Int J Biochem Cell Biol. 2013 Oct;45(10):2266-79. doi: 10.1016/j.biocel.2013.05.001. Epub 2013 May 11. Review.


β1 integrin gene excision in the adult murine cardiac myocyte causes defective mechanical and signaling responses.

Li R, Wu Y, Manso AM, Gu Y, Liao P, Israeli S, Yajima T, Nguyen U, Huang MS, Dalton ND, Peterson KL, Ross RS.

Am J Pathol. 2012 Mar;180(3):952-62. doi: 10.1016/j.ajpath.2011.12.007. Epub 2012 Jan 14.


Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.

Dahiya S, Givvimani S, Bhatnagar S, Qipshidze N, Tyagi SC, Kumar A.

J Immunol. 2011 Sep 1;187(5):2723-31. doi: 10.4049/jimmunol.1101342. Epub 2011 Aug 1.


Delay in diagnosis of muscle disorders depends on the subspecialty of the initially consulted physician.

Spuler S, Stroux A, Kuschel F, Kuhlmey A, Kendel F.

BMC Health Serv Res. 2011 May 4;11:91. doi: 10.1186/1472-6963-11-91.


Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.

Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL.

Mol Med. 2011 May-Jun;17(5-6):457-65. doi: 10.2119/molmed.2011.00049. Epub 2011 Feb 7. Review.


Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.

Kumar A, Bhatnagar S, Kumar A.

Am J Pathol. 2010 Jul;177(1):248-60. doi: 10.2353/ajpath.2010.091176. Epub 2010 May 14.


Therapeutic targeting of signaling pathways in muscular dystrophy.

Bhatnagar S, Kumar A.

J Mol Med (Berl). 2010 Feb;88(2):155-66. doi: 10.1007/s00109-009-0550-4. Epub 2009 Oct 9. Review.


Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.

Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A.

Hum Mol Genet. 2009 Jul 15;18(14):2584-98. doi: 10.1093/hmg/ddp191. Epub 2009 Apr 28.


Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

Rose FF Jr, Mattis VB, Rindt H, Lorson CL.

Hum Mol Genet. 2009 Mar 15;18(6):997-1005. doi: 10.1093/hmg/ddn426. Epub 2008 Dec 12.


Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1.

Steen MS, Adams ME, Tesch Y, Froehner SC.

Mol Biol Cell. 2009 Jan;20(1):146-52. doi: 10.1091/mbc.E08-08-0811. Epub 2008 Oct 22.


Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy.

Mozzetta C, Minetti G, Puri PL.

Int J Biochem Cell Biol. 2009 Apr;41(4):701-10. doi: 10.1016/j.biocel.2008.08.033. Epub 2008 Sep 2. Review.


Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors.

Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK.

Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4318-22. doi: 10.1073/pnas.0709144105. Epub 2008 Mar 11.


Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice.

Dogra C, Srivastava DS, Kumar A.

Mol Cell Biochem. 2008 May;312(1-2):17-24. doi: 10.1007/s11010-008-9716-6. Epub 2008 Feb 17.


Transgenic overexpression of ADAM12 suppresses muscle regeneration and aggravates dystrophy in aged mdx mice.

Jørgensen LH, Jensen CH, Wewer UM, Schrøder HD.

Am J Pathol. 2007 Nov;171(5):1599-607.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk